Laboratorios Rubió is a company that is currently
undergoing a process of expansion and growth
(in thousands of €)
Rubió is a company in the midst of expansion and growth. The upward progression of turnover is an indicator of the good work carried out. Our strategic plan focuses on internationalization and R&D for the development of new products.
Turnover for 2024 has reached €181 million, representing an annual increase of 38.23%. By markets, in Spain the increase has been 43.03% and 14.60% internationally.
For 2025, turnover is expected to continue growing to reach €193 million, a 6% increase.
The company’s workforce comprised 284 people at the end of 2024, 74% more than in 2020, with the commercial and industrial operations areas experiencing the greatest growth.
Rubió is a company that trusts the people who are part of its organization, recognizes their professional value, and allocates resources to maintaining a good working environment while fostering opportunities, personal development, and work-life balance.
As part of the company’s strategic plan to continue growing and drive internationalization, Rubió has made a firm commitment to expansion in key areas such as nutraceuticals, metabolomics, and diagnostic innovation.
In 2021, Fisiopharma, specialized in nutraceuticals, was acquired, and in 2022 Rubió Metabolomics, a leader in clinical metabolomics. This strategy was reinforced with the acquisition of Rubió Nutraceuticals in Italy in 2023 and Nutribrain in 2024, focused on cognitive health. In parallel, Rubió founded CIMA Sciences in 2022 in the United States for the international commercialization of OWLiver®, a non-invasive diagnostic test for MASLD/MASH.
The company concentrates its investments on expanding production capacity—an expansion process underway since 2021, aimed at nearly doubling industrial capacity in three years—and in various R&D projects for both European and North American markets, maintaining its commitment to innovation, quality, and internationalization.
Investments (in thousands of €)
Two major areas of Pharmaceutical and In-vitro Diagnosis
and nutrition for special conditions.
Laboratorios Rubió’s business activity is structured into four major areas: Pharmaceutical, OTC, Metabolomics, and Diagnostics. Our extensive vademecum includes pharmaceutical products focused on therapeutic areas such as Rheumatology, Musculoskeletal system, Nephrology, Urology, Andrology, Digestive/Gastro, Central Nervous System, Gynecology, Radiotherapeutic Oncology, and Hepatology.
We manufacture and sell well-established pharmaceutical drugs with a solid reputation and introduce new products annually through our R&D and partnerships with third parties.
Our Metabolomics division focuses on liver research, R&D, and non-invasive diagnostic tests.
Our Diagnostics division offers in-vitro tests to determine lipoprotein fractions for cardiovascular risk and non-invasive diagnostic tools for assessing all lesional phases of MASLD.
The OTC business unit provides complete formulas for food supplements for osteoarticular and muscular health.
Founded in 2014, this subsidiary acts as a “patent box” with the aim of strengthening the R&D&I area of Laboratorios Rubió. In this context, the company’s priority strategy is based on extending the lifecycle of its own products, collaborating in new research programs that align with the company’s therapeutic objectives, and establishing strategic alliances with research foundations in related fields.
Biosfer Teslab, a spin-off company from the Universitat Rovira i Virgili (URV) and the Pere Virgili Health Research Institute (IISPV), is a company in which Laboratorios Rubió holds a stake and specializes in the development of in vitro diagnostic tests to improve cardiovascular assessment in high-risk patients.
A national company specialized in nutraceuticals aimed at musculoskeletal health, which will grow in the coming years both in products from other therapeutic areas and in other countries. This growth is reinforced by the acquisition of Rubió Nutraceuticals in Italy in 2023.
A company specialized in clinical metabolomics, recognized nationally and internationally for the development of innovative solutions for non-invasive diagnosis and monitoring of metabolic diseases. Rubió Metabolomics will expand its presence both in new markets and in other therapeutic areas in the coming years.
Joint venture founded in 2022 in the United States by Rubió for the international commercialization of OWLiver®, the leading non-invasive diagnostic test for MASLD/MASH. CIMA Sciences will consolidate expansion in the American market and strengthen the internationalization of OWLiver®.
A company focused on cognitive health through high-quality nutraceuticals. Nutribrain is part of Rubió’s growth in innovative areas for comprehensive wellbeing, with online sales at both the national and international digital level.
Laboratorios Rubió conducts extensive international sales, maintaining business relationships in over 70 countries with a network of more than 80 strategic partners. International business constitutes over 70% of our manufactured units, underscoring our successful internationalization efforts and significant growth in recent years. Developing new markets is a priority for Laboratorios Rubió.
Our projects with strategic partners focus on key therapeutic areas, R&D, and healthcare advancements allowing us to set very high growth goals. This ensures our pharmaceutical products reach a broader patient audience through an efficient global supply chain, supporting our mission to enhance global healthcare.
With the recent acquisition of OWL Metabolomics, the company takes a prominent position in the metabolomics sector, with its own developments of diagnostic tests based on metabolomics and developments and studies for the pharmaceutical industry and main research centers. The knowledge generated in one of the most innovative “omics” sciences today, in liquid chromatography and mass spectrometry (LC/MS) platforms, is key for internal research projects as well as for third parties. to diseases with a high component of metabolic syndrome and liver diseases. In turn, the complementary technologies of Biosfer Teslab and OWL Metabolomics provide robustness to the company’s metabolomics offer.
Rubió has a modern, proprietary production plant located in the town of Castellbisbal (Barcelona). With 2,900 m² built and an annual installed production capacity of over 10 million units of finished product, this center is equipped with the highest technology, enabling the preparation of solid oral forms, especially tablets, coated tablets, capsules, and single-dose and multi-dose powders, as well as the primary and secondary packaging of these types of pharmaceutical forms in accordance with GMP regulations.
These facilities also house the quality control and galenic development laboratories, with a pilot plant necessary for executing scale-up processes at an industrial level, and finished product warehouses.
This plant is in a constant phase of renovation, and the existence of an annual investment plan includes the improvement and replacement of equipment and facilities, to achieve the highest standards of quality and productivity.
Laboratorios Rubió is a company whose commitment to transparency is strengthened through the disclosure, as stated in Spanish Farmaindustria’s Code of Best Practices, of transfers of value occurring each year as a result of interactions with healthcare organisations and professionals.
